BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Research

Antengene Clears U.S. IND for Phase I Trial of ATG-031 Antibody

- ATG-031, discovered and developed in-house by Antengene, is the world's first anti-CD24 antibody to advance to the clinic in oncolog...

May 18, 2023 | News

BPAC and Novari Health Announce eReferral Integration

This bi-directional integration enables clinicians using the BPAC eReferral system to transmit referrals from within their practice management solution (PM...

May 16, 2023 | News

Hummingbird Bioscience, Merck to Evaluate HMBD-001 in Lung Carcinoma

Hummingbird Bioscience enters a clinical trial collaboration and supply agreement with Merck to evaluate HMBD-001, a potentially best-in-class anti-HER3 ...

May 16, 2023 | News

Amgen and TScan collaborate to identify new Crohn's disease targets.

TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million &nbs...

May 12, 2023 | News

Fujitsu partners with Takeda and National Cancer Center Japan to analyze and visualize ovarian cancer patient journey

Fujitsu today announced that it has conducted a joint research project with Takeda Pharmaceutical Company Limited and the National Cancer Center Japan to a...

May 12, 2023 | News

Nona Biosciences partners with PharmaEssentia Innovation Research Center

"We are pleased to enter this strategic collaboration with PharmaEssentia," Jingsong Wang, M.D., PhD, Chairman of Nona Biosciences, said, " PharmaEsse...

May 12, 2023 | News

CytoMed collaborates with MD Anderson to advance Gamma Delta T Cells in Oncology

CytoMed Therapeutics Limited (Nasdaq: GDTC) ("CytoMed" or the "Company"), a biopharmaceutical company focused on harnessing its licensed proprietary techno...

May 11, 2023 | News

Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases

-Boehringer Ingelheim announced that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 stu...

May 11, 2023 | News

Thermo Fisher & Pfizer team up to bring cancer testing to global markets

Increasing localized access can provide faster results for patients while potentially improving patient outcomes Agreement aims to enable greater access t...

May 10, 2023 | News

Gencurix Reports Clinical Results of 15-Year Follow-Up Prognostic Test for Cancer Patients in Korea and Japan

Gencurix announced clinical results of its prognostic test for breast cancer patients at the Global Breast Cancer Conference 2023. The study, 'Long-te...

May 10, 2023 | News

Biosion shares Anti-CD40 Agonistic Antibody discovery and development data at PEGS

BSI-038 is an anti-CD40 agonistic monoclonal antibody, discovered through Biosion's H³ antibody discovery platform. BSI-038 exhibits enhanced bin...

May 09, 2023 | News

Bliss Biopharmaceutical Collaborates with Eisai for Clinical Trial of BB-1701 with Strategic Option

This collaboration with Eisai is an important advancement in BlissBio's corporate development plan to further develop BB-1701 globally and help advance BB-...

May 08, 2023 | News

GenAssist's GEN6050 Base Editing Product Submits Pre-IND Application to FDA

Suzhou GenAssist Therapeutic Co.,Ltd recently announced its pre-IND application of their first base editing product, GEN6050 and the acceptance by the FDA....

May 08, 2023 | News

Telix to Provide Illuccix® to Bayer for Global Phase III Prostate Cancer Study, Including Japan

This global study is investigating the efficacy of Bayer's androgen receptor inhibitor (ARi) darolutamide plus androgen deprivation therapy (ADT) versus AD...

May 08, 2023 | News

Stay Connected